Biotech News

Emergent BioSolutions Successfully Refinances Term Loan, Amends Asset-backed Loan Facility and Increases Financial Flexibility

Emergent BioSolutions (EBS)Emergent BioSolutionsCompany update

Refinancing extends maturities, reduces interest expense and positions Emergent for durable, long-term growth as part of its multi-year transformation plan GAITHERSBURG, Md., April 16, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company has closed on a

Related news

Emergent BioSolutions

Emergent BioSolutions is a biodefense and specialty products company focused on public-health preparedness, vaccines, and medical countermeasures. Its business is centered on government and specialty healthcare contracts.

Recent company news

Stock data

Close
4.82 USD
Market cap
423.61M USD
Exchange
NYSE
Sector
Biopharma
Location
United States